Peptides: The Hype, Risks and Regulatory Challenges

Peptides, short chains of amino acids, have gained popularity among influencers, athletes, and health enthusiasts for their alleged benefits in injury repair, weight loss, and anti-aging. However, the recent surge in interest has raised concerns about the safety and regulation of these substances.

Some peptides occur naturally in the body and play crucial roles in various physiological processes. For instance, hormones like insulin, oxytocin, and vasopressin are peptides that regulate blood sugar levels, social behaviors, and water retention, respectively.

In recent years, there has been a growing interest in using peptides for therapeutic purposes, including weight loss, anti-aging, and injury recovery. This has led to the development of approved prescription medications based on synthetic peptides, such as semaglutide and tirzepatide, which mimic natural hormones.

However, many peptides on the market have not undergone rigorous regulatory processes and are being sold as unregulated, experimental substances. These peptides are often self-injected, raising concerns about their safety and efficacy.

According to Dr. Luke Turnock, a criminology expert, peptides were initially popular among powerlifters and bodybuilders in the 2010s, particularly growth-hormone-releasing peptides like GHRP-2 and GHRP-6. The use of peptides has since expanded to a broader audience, with high-profile figures like US podcaster Joe Rogan promoting them.

Experts warn that many experimental peptides lack scientific evidence to support their claimed benefits. While some studies show potential in animal and cell research, human data is often lacking or flawed. Moreover, many popular peptides are not considered medicines in the UK, making them unregulated by the Medicines and Healthcare products Regulatory Agency (MHRA).

The MHRA has emphasized that making medicinal claims or using peptides as medicines requires authorization. They are taking action to ensure regulatory compliance, including removing unauthorized products from the market. The agency also disregards claims of 'research purposes' if there is evidence that products are intended for human use.

Prof. Adam Taylor from Lancaster University highlights the risks of using experimental peptides. He explains that pre-clinical studies do not guarantee safety or efficacy in humans, and there are concerns about product purity, potential contaminants, and unexpected effects on the body's pathways. Additionally, the lack of monitoring and the risks associated with self-injection further complicate the situation.